发明授权
US07629334B1 Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
有权
作为激素替代疗法（HRT）组合物组分的Mesoprogrestins（孕酮受体调节）
- 专利标题： Mesoprogrestins (progesterone receptor modulations) as a component of compositions for hormone replacement therapy (HRT)
- 专利标题（中）： 作为激素替代疗法（HRT）组合物组分的Mesoprogrestins（孕酮受体调节）
-
申请号： US10433984申请日： 2000-08-31
-
公开(公告)号： US07629334B1公开(公告)日： 2009-12-08
- 发明人: Kristof Chwalisz , Walter Elger , Gerd Schubert
- 申请人： Kristof Chwalisz , Walter Elger , Gerd Schubert
- 申请人地址： DE Berlin
- 专利权人： Bayer Schering Pharma Aktiengesellschaft
- 当前专利权人： Bayer Schering Pharma Aktiengesellschaft
- 当前专利权人地址： DE Berlin
- 代理机构： Millen, White, Zelano, Branigan, P.C.
- 国际申请： PCT/US00/23771 WO 20000831
- 国际公布： WO01/34126 WO 20010517
- 主分类号： A61K31/56
- IPC分类号： A61K31/56 ; C07J1/00 ; C07J6/00
摘要：
The use of mesoprogestins as pharmaceutical components for the manufacture of a medicament for hormone replacement therapy (HRT) and as components for the combined use together with an estrogen for the manufacture of a medicament for HRT as well as in respective HRT-methods and methods of treating hormone deficiency and hormone irregularity symptoms. Mesoprogestins are defined as compounds possessing both agonistic and antagonistic activities at the progesterone receptor (PR) in vivo. They stabilize the function of PR at an intermediate level of agonistic and antagonistic. Corresponding functional states cannot be achieved with progestins or antiprogestins. J867, J912, J956 and J1042 are the mesoprogestins preferred herein.
信息查询
